ICON Public Company (ICLR) Q1 2025 earnings summary

Executive summary

• Q1 2025 was marked by a challenging environment with elevated cancellations, delays in clinical trial starts, and cautious customer behavior, especially in biotech, impacting near-term revenue and bookings.

• Large pharma demand was mixed due to budget constraints and loss of exclusivity, but win rates improved and strategic partnerships showed growth opportunities.

• Operational focus on cost control, process standardization, and digital innovation, including new AI-enabled tools, supported margin performance and efficiency.

• Strong balance sheet enabled assertive capital deployment, including $250M in share repurchases in Q1, and flexibility for M&A.

• Net business wins totaled $2,022M with a book-to-bill ratio of 1.01; backlog reached $24.7B, up 6% year-over-year.

Financial highlights

• Q1 2025 revenue was $2,001.3M, down 4.3% year-over-year (3.2% on constant currency).

• Adjusted EBITDA was $390.7M (19.5% margin), down from $444M (21.2%) in Q1 2024.

• Adjusted net income was $258.3M ($3.19 per share), with adjusted EPS down from $3.47 in Q1 2024.

• US GAAP net income was $154.2M ($1.90 per diluted share), down from $2.25 per share in Q1 2024.

• Free cash flow was $239.3M; cash and equivalents were $526.7M at quarter-end, up from $398M a year earlier.

Outlook and guidance

• Full-year 2025 revenue guidance reduced to $7,750–$8,150M, a decrease of 6.4% to 1.6% year-over-year, mainly due to removal of two next-gen COVID trials and continued elevated cancellations.

• Full-year adjusted EPS guidance is $12.75–$14.25, compared to $14.00 in 2024.

• Guidance assumes sustained elevated cancellation rates and a cautious book-to-bill outlook for 2025.

• EBITDA margin for the year expected to be about 1% lower than 2024, with gradual improvement and exit rate near 21%.

• FX expected to be a modest tailwind (~1%) for the full year; capital expenditure expected to be around $200M.